Skye Bioscience, Inc.
Skye Bioscience, Inc.
Join ActionIf you are a Skye Bioscience investor who suffered a loss and would like to learn more, you can provide your information below:
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Skye Biosciences, Inc. (“Skye” or the “Company”) (NYSE: SKYE) and reminds investors of the January 16, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) nimacimab was less effective than Defendants had led investors to believe; (2) accordingly, nimacimab’s clinical, regulatory, and commercial prospects were overstated; and (3) as a result, Defendants’ public statements were materially false and misleading at all relevant times.
Lead Plaintiff Deadline: January 16, 2026
📞 Call Partner Josh Wilson at 877-247-4292 or 212-983-9330 (Ext. 1310)
💻 Or submit your information below to learn about your rights.